2023 World Conference on Lung Cancer (Posters)-EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the safety and efficacy of aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations who were intolerant to osimertinib treatment. The study included 9 NSCLC patients from a hospital in China. The primary endpoint was the 3-month conversion success rate, and secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and overall survival (OS). The median age of the patients was 64 years, with a majority being female. Grade 3 rash and grade 2 platelet count decrease were observed as adverse events. The 3-month conversion success rate was 100%, with an ORR of 33.3% and DCR of 100%. Both PFS and OS were not reached. Hematologic toxicity and other adverse events were not reported. The study concluded that aumolertinib is a safe and effective option for locally advanced or metastatic EGFR-mutant NSCLC patients who are intolerant to osimertinib treatment.

Asset Subtitle

Qinhong Zheng

Meta Tag

Speaker Qinhong Zheng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

aumolertinib

EGFR-TKI

NSCLC

osimertinib treatment

efficacy

safety

progression-free survival

ORR

DCR